You are here: Industry Insights > M&A

News List

Pharma M&A activity up 17 percent year-on-year in H1 of 2020 europeanpharmaceuticalreview
November 06, 2020
A new report has highlighted that despite the pandemic, pharma M&A activity rose but deal value fell in the first half of 2020.
10 Predictions on How COVID-19 Will Impact Middle Market M&A prnewswire
June 15, 2020
The coronavirus outbreak has impacted just about every aspect of daily life on a global scale, and middle market M&A is no exception.
Life science M&A activity reached $357bn in 2019, report finds europeanpharmaceuticalreview
January 15, 2020
According to new research, M&As within the life science industry reached a high last year and is expected to continue its growth in 2020.
The top 10 largest biopharma M&A deals in 2019 fiercepharma
January 07, 2020
Biopharma M&A got a big boost moneywise in 2019. The three largest—Bristol-Myers Squibb for Celgene, AbbVie for Allergan, and Amgen for Celgene’s psoriasis drug Otezla—together delivered more than $150 billion. Valued at $74 billion ...
Sanofi aims to save €2B through job cuts, smarter buying fiercepharma
December 12, 2019
Like many a corporate rejuvenation plan, CEO Paul Hudson's blueprint for Sanofi includes some hefty cost cutting.
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already fiercepharma
September 26, 2019
Amgen eventually agreed to pick up Otezla in a $13.4 billion deal in August, which some analysts called savvy despite concerns the buyout would spark FTC pushback of its own: The drugmaker already markets blockbuster TNF inhibitor Enbrel.
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A fiercepharma
July 13, 2019
Aiming to break into a three-way battle among large drugmakers in the brand-new CGRP migraine class, tiny Biohaven Pharmaceutical has released detailed data for its own candidate, which one group of analysts figures could reach blockbuster status.
Post-Alcon Novartis eyes M&A in ophthalmic digital therapeutics fiercepharma
April 10, 2019
Now that Alcon is officially off on its own, what is Novartis’ remaining eye medicine business looking at next? According to Nikos Tripodis...
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report fiercepharma
February 22, 2019
This year is already shaping up to be a big one for biopharma mergers and acquisitions, with Bristol-Myers Squibb’s planned $74 billion buyout of Celgene well underway.
JP Morgan: no expert consensus on 2019 capital outlook for bio/pharma pharmaceutical-technology
February 03, 2019
Expert speakers at this year’s JPM Healthcare Conference disagreed in their optimism for capital markets and M&A in 2019.

Previous page 1 2 3 4 5 6 7 Next page